NEW YORK – Ayala Pharmaceuticals and ArcherDx said today they will work together to develop companion diagnostics that can gauge whether cancer patients have Notch-activating genetic mutations and fusions and will respond to certain targeted drugs.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.